EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment

Kristen S Young, Sean W Fanning

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci207633 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Kristen S Young und 1 weiteren Autor:innen. Hauptthemen laut MEDLINE: Breast Neoplasms, Tumor Microenvironment, Estrogen Receptor alpha, Selective Estrogen Receptor Modulators. Die Arbeit nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

One in eight women will be diagnosed with breast cancer in their lifetime. Most breast cancers express estrogen receptor α (ERα) and depend on its signaling, which promotes tumor growth, survival, and metastatic spread through hormone-dependent transcriptional reprogramming. Selective estrogen receptor degraders/downregulators (SERDs), such as fulvestrant (faslodex), which was FDA approved in 2002, are second-line endocrine therapies for the treatment of advanced metastatic disease. Tumors containing activating hotspot mutations in ESR1 (the gene encoding ERα) retain some sensitivity to fulvestrant but require higher doses to achieve inhibition of the mutant receptor. Substantial efforts to develop next-generation SERDs with improved pharmacology over fulvestrant have led to the FDA approval of the first-in-class orally available SERD elacestrant (Orserdu), followed by imlunestrant (Inluriyo), and the anticipated approval of several more therapies. Excitingly, recent studies show that in addition to their previously described antitumoral mechanisms, SERDs also act by increasing antitumor immunity. In this Review, we detail the current SERD clinical landscape and our emerging understanding of the interplay among SERDs, breast cancer cells, and the tumor immune microenvironment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTumor MicroenvironmentEstrogen Receptor alphaSelective Estrogen Receptor ModulatorsHumansFemaleAnimalsFulvestrant

Substanzen

Estrogen Receptor alphaSelective Estrogen Receptor ModulatorsESR1 protein, humanFulvestrant

Zitieren

APA

Young, K. S., & Fanning, S. W. (2026). Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment. Journal of Clinical Investigation. https://doi.org/10.1172/jci207633

Vancouver

Young KS, Fanning SW. Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment. Journal of Clinical Investigation. 2026. doi:10.1172/jci207633

BibTeX
@article{Young2026,
  author = {Young, Kristen S and Fanning, Sean W},
  title = {Selective estrogen receptor degraders and their effect on the breast cancer immune microenvironment},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci207633}
}
Kostenlos starten →